JP7421499B2 - 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 - Google Patents

腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 Download PDF

Info

Publication number
JP7421499B2
JP7421499B2 JP2020564095A JP2020564095A JP7421499B2 JP 7421499 B2 JP7421499 B2 JP 7421499B2 JP 2020564095 A JP2020564095 A JP 2020564095A JP 2020564095 A JP2020564095 A JP 2020564095A JP 7421499 B2 JP7421499 B2 JP 7421499B2
Authority
JP
Japan
Prior art keywords
metalrestin
cells
formula
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524844A (ja
JP2021524844A5 (https=
JPWO2019222380A5 (https=
Inventor
ルドロフ、ウード
コズロフ、セルゲイ
ホセ マルガン、フアン
フアン、スイ
パトナイク、サマルジット
シー． ブレイステッド、ジョン
ティー． サウソール、ノエル
フェレール、マーク
デクストラス、クリストファー
ハスラム、ジョン
バルテゾール、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2021524844A publication Critical patent/JP2021524844A/ja
Publication of JP2021524844A5 publication Critical patent/JP2021524844A5/ja
Publication of JPWO2019222380A5 publication Critical patent/JPWO2019222380A5/ja
Priority to JP2024003447A priority Critical patent/JP7736825B2/ja
Application granted granted Critical
Publication of JP7421499B2 publication Critical patent/JP7421499B2/ja
Priority to JP2025142520A priority patent/JP2026000929A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2020564095A 2018-05-15 2019-05-15 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 Active JP7421499B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024003447A JP7736825B2 (ja) 2018-05-15 2024-01-12 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
JP2025142520A JP2026000929A (ja) 2018-05-15 2025-08-28 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671964P 2018-05-15 2018-05-15
US62/671,964 2018-05-15
PCT/US2019/032461 WO2019222380A1 (en) 2018-05-15 2019-05-15 Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024003447A Division JP7736825B2 (ja) 2018-05-15 2024-01-12 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法

Publications (4)

Publication Number Publication Date
JP2021524844A JP2021524844A (ja) 2021-09-16
JP2021524844A5 JP2021524844A5 (https=) 2022-05-23
JPWO2019222380A5 JPWO2019222380A5 (https=) 2022-05-23
JP7421499B2 true JP7421499B2 (ja) 2024-01-24

Family

ID=66691010

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020564095A Active JP7421499B2 (ja) 2018-05-15 2019-05-15 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
JP2024003447A Active JP7736825B2 (ja) 2018-05-15 2024-01-12 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
JP2025142520A Pending JP2026000929A (ja) 2018-05-15 2025-08-28 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024003447A Active JP7736825B2 (ja) 2018-05-15 2024-01-12 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
JP2025142520A Pending JP2026000929A (ja) 2018-05-15 2025-08-28 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法

Country Status (7)

Country Link
US (2) US20210186972A1 (https=)
EP (2) EP4721727A2 (https=)
JP (3) JP7421499B2 (https=)
AU (2) AU2019271208B2 (https=)
CA (1) CA3100211A1 (https=)
ES (1) ES3061722T3 (https=)
WO (1) WO2019222380A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2022159650A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
US20260028342A1 (en) * 2022-07-29 2026-01-29 The University Of North Carolina At Chapel Hill Enhancing antimetastasis activity using targeted protein degradation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121069A2 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20100136105A1 (en) 1999-06-30 2010-06-03 Lipocine, Inc. Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2011516587A (ja) 2008-04-18 2011-05-26 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
JP2015502367A (ja) 2011-12-16 2015-01-22 アメリカ合衆国 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法
WO2017054754A1 (en) 2015-09-30 2017-04-06 Athenex HK Innovative Limited Oral taxane compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877966B1 (en) * 2015-08-10 2018-01-30 Eugene J. Oliva Combination therapy for the inhibition of metastasis and tumorigenesis
US11241436B2 (en) * 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136105A1 (en) 1999-06-30 2010-06-03 Lipocine, Inc. Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2009121069A2 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
JP2011516587A (ja) 2008-04-18 2011-05-26 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
JP2015502367A (ja) 2011-12-16 2015-01-22 アメリカ合衆国 腫瘍転移及び腫瘍形成の予防及び治療のための化合物並びに方法
WO2017054754A1 (en) 2015-09-30 2017-04-06 Athenex HK Innovative Limited Oral taxane compositions and methods

Also Published As

Publication number Publication date
JP2024050620A (ja) 2024-04-10
JP2021524844A (ja) 2021-09-16
US20210186972A1 (en) 2021-06-24
AU2025203402A1 (en) 2025-06-19
AU2019271208B2 (en) 2025-02-13
JP2026000929A (ja) 2026-01-06
JP7736825B2 (ja) 2025-09-09
US20240316056A1 (en) 2024-09-26
AU2019271208A1 (en) 2020-12-03
EP3793523B8 (en) 2026-01-21
ES3061722T3 (en) 2026-04-07
CA3100211A1 (en) 2019-11-21
AU2025203402A9 (en) 2026-03-05
EP3793523B1 (en) 2025-11-12
EP3793523A1 (en) 2021-03-24
WO2019222380A1 (en) 2019-11-21
EP4721727A2 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
JP7421499B2 (ja) 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
JP7472080B2 (ja) メラノーマの処置および診断
Liu et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin
Liu et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway
CN103154246B (zh) 用于治疗白血病的组合物和方法
CN103119160B (zh) 用于调节代谢的组合物和方法
JP2020059748A (ja) ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター
WO2008098351A1 (en) Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
Wang et al. Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide
ES2991090T3 (es) Inhibidores de KDM4
US11789012B2 (en) Cell death biomarker
WO2022018667A1 (en) Combination therapies using cdk2 and cdc25a inhibitors
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
KR20160110952A (ko) 암을 치료하기 위한 신규한 방법
JP2020501544A (ja) 抗がん化合物およびその使用
Ota et al. Suppression of FGFR3-and MYC-dependent oncogenesis by tubacin: Association with HDAC6-dependent and independent activities
CN112218627B (zh) 前药及其在医学上的应用
US20200276181A1 (en) Thienoisoquinolines and their derivatives for targeting tubulin, ch-tog, aurora a kinase, tpx2, cdk5rap2 and/or aspm
US20150045363A1 (en) Hedgehog Pathway Inhibition for Cartilage Tumor and Metachondromatosis Treatment
US20240294478A1 (en) Anti-cancer compounds and methods of use
CN111346096B (zh) 一种用于预防或治疗胶质瘤的药物组合物
CN111346101B (zh) Tamatinib在制备治疗胶质瘤的药物中的用途
WO2017119988A2 (en) Radioprotection by wnt activation
Liu et al. Genetic alterations in the PI3K/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mTOR
CN119300830A (zh) 用于治疗癌症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240112

R150 Certificate of patent or registration of utility model

Ref document number: 7421499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150